Vimpat Receives Expanded Indication to Treat Seizures in Infants
October 20, 2021FDA Approves Expanded Indications for Cyltezo
October 22, 2021October 20, 2021 – The U.S. FDA has amended the emergency use authorizations (EUAs) for COVID-19 vaccines to expand the use of booster shots in eligible individuals.
- A single booster dose of the Moderna COVID-19 vaccine or the Pfizer COVID-19 vaccine (marketed
under the brand name Comirnaty®) can be administered at least six months after completion of
the primary series to individuals:
- 65 years of age and older;
- 18 through 64 years of age at high risk of severe COVID-19; or
- 18 through 64 years of age with frequent institutional or occupational exposure to SARS- CoV-2, the virus that causes COVID-19.
- A single booster dose of the Janssen (Johnson & Johnson) COVID-19 vaccine can be administered at least two months following completion of the single-dose primary regimen to individuals 18 years of age and older.
- Each of the three COVID-19 vaccines available in the United States (Pfizer/BioNTech, Moderna,
and Janssen) can be mix-and-matched to provide a booster dose in eligible individuals who
received a different COVID-19 vaccine for primary vaccination.
- For instance, an individual who received primary vaccination with the Moderna vaccine can receive a booster dose of the Pfizer/BioNTech or Janssen vaccines if needed.